elasomeran

all catalysts(0)

nothing on the calendar yet

News(5)

• After a brief storm of political headwinds, mRNA is back with strong momentum
  A year to the day after the Trump administration slashed $500 million in funding from mRNA-based programs, the FDA approved Moderna’s flu vaccine based on the technology. Weeks later, Moderna and M…
  biospace · 16d ago
• Is Moderna, Merck's mRNA cancer vaccine win the start of a 'personalized medicine revolution'?
  The announcement from Merck & Co. and Moderna last month that their mRNA cancer vaccine had successfully lengthened patient survival in a phase 3 study affirmed the two companies' years of hard wor…
  fiercebiotech · 28d ago
• BioNTech halts mid-stage trial of personalized mRNA vaccine in colorectal cancer
  Shares of Germany-based BioNTech were down as much as 8% Friday after announcing a Phase 2 trial of autogene cevumeran would be discontinued for futility. The news follows Merck and Moderna’s Phase…
  biospace · 1mo ago
• Moderna stock nearly doubles as Merck-partnered mRNA cancer vaccine meets Phase 3 goal
  Melanoma was slower to recur in patients receiving Merck and Moderna's mRNA vaccine with Keytruda, supporting use of the combination in adjuvant treatment. The partners plan to take the data to the…
  biospace · 1mo ago
• Moderna maintains 10% growth target despite Phase 3 norovirus miss
  Moderna’s norovirus vaccine failed in a Phase 3 trial, but the company still has faith in an ambitious revenue growth target thanks to ex-U.S. vaccine sales and a unanimous FDA adcomm win for mFLUS…
  biospace · 2mo ago